Search the Newsreel

Chubb Ltd (CB) Stock News Today

Mirae Asset Global Investments Co. Ltd. Purchases 6,466 Shares of Royal Caribbean Cruises Ltd. $RCL

Bristol Myers Squibb announces new $2.3bn campus in the US

Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design …

Abbott India Shares Fall Over 2%

Thompson Investment Management Inc. Has $1.28 Million Stock Position in Abbott Laboratories $ABT

Toth Financial Advisory Corp Decreases Stock Holdings in Abbott Laboratories $ABT

TBBB|Bbb Foods Inc|Price:49.440|Chg%:+1.380

Bbb Foods Inc (TBBB) is trading at $49.77, up 0.50%, with a market cap of $6.04 billion. The company recently reported strong Q2 2026 earnings, with revenue up 39% and same-store sales growing 20%. Analysts currently rate TBBB as a "Buy" with a target …

5 Revealing Analyst Questions From Goodyear’s Q2 Earnings Call

5 Revealing Analyst Questions From Goodyear's Q2 Earnings Call Goodyear's second quarter saw global sales fall in line with broader industry softness, with the market reacting negatively to ongoing margin pressure and a continued year-over-year revenue decline. Management attributed the quarter's results to persistent …

Abbott Laboratories $ABT Shares Sold by Cox Capital Mgt LLC

West Branch Capital LLC significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 83.5% in the second quarter, selling 13,061 shares and retaining 2,576 shares worth $234,000. Despite this sell-off, institutional investors collectively own 75.18% of Abbott’s stock. Abbott reported strong Q2 earnings of …

Exchange Traded Concepts LLC Has $7.02 Million Position in Royal Caribbean Cruises Ltd. $RCL

Exchange Traded Concepts LLC significantly increased its stake in Royal Caribbean Cruises Ltd. (NYSE:RCL) by 722.1% during the second quarter, now holding 22,098 shares valued at approximately $7.02 million. Royal Caribbean exceeded quarterly expectations with $4.21 EPS and $4.83 billion in revenue, guiding for …

Assenagon Asset Management S.A. Lowers Stake in Hubbell Inc $HUBB

Assenagon Asset Management S.A. significantly reduced its stake in Hubbell Inc (NYSE:HUBB) by 88.2% in the second quarter, now holding 3,929 shares valued at $2.06 million. Despite this reduction, Hubbell reported strong financial results, with quarterly EPS of $5.52 and revenue of $1.71 billion, …

ABN Amro Investment Solutions Acquires 5,232 Shares of Royal Caribbean Cruises Ltd. $RCL

Abbott Laboratories Aktie | US0028241000 | ETR:ABL | News & Aktienkurs | FRA:ABL

Press Release: BBVA Argentina Announces Second Quarter 2026 Financial Results Schedule

BBVA Argentina (NYSE: BBAR; BASE: BBAR) announced the schedule for its second-quarter 2026 financial results release. The results will be disclosed on August 21, 2026, after the market close. A conference call and webcast will follow on August 22, 2026, at 11:00 AM ET.

Top Abbott Executive Makes Bold Move With Fresh Insider Stock Sale

An executive at Abbott Laboratories (ABT), Louis H. Morrone, recently sold 5,850 shares of company stock for $642,505. This insider transaction provides investors with additional data to consider regarding the company's current valuation. Abbott's stock performance and analyst ratings are influenced by its strong …

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study evaluated epcoritamab monotherapy against investigator's choice of chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory …

Chubb Limited (NYSE:CB) Announces Quarterly Dividend of $1.02

Chubb Limited (NYSE:CB) declared a quarterly dividend of $1.02 per share, payable on October 2nd to shareholders of record on September 11th. This dividend represents an annualized payout of $4.08 and a yield of approximately 1.2%, marking the company's 31st consecutive year of dividend …

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Bristol Myers Squibb announced that the U.S. FDA has granted accelerated approval for ZENBEXUS™ (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for adult patients with multiple myeloma who have received at least one prior line of therapy. This approval, based on …

Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?

AbbVie Inc. (NYSE:ABBV) reported its first-quarter 2026 financial results, delivering worldwide net revenues of $15.002 billion, an increase of 12.4% on a reported basis (10.3% operationally). The company posted GAAP diluted EPS of $0.39 and adjusted diluted EPS of $2.65, which exceeded internal expectations …

BBB FOODS INC (TBBB): Morgan Stanley trims stake to 3.9% of Class A shares

Morgan Stanley has reported an updated passive ownership position in BBB FOODS INC (TBBB) Class A Common Shares, trimming its stake to 3.9%. According to a Schedule 13G/A amendment, Morgan Stanley now holds shared voting power over 2,916,513 shares and shared dispositive power over …

US FDA approves Bristol Myers' blood cancer treatment

The U.S. FDA has approved Bristol Myers Squibb's combination treatment, iberdomide, for patients with a rare form of blood cancer called multiple myeloma. This treatment is intended for patients whose illness has relapsed or not responded to other therapies. Iberdomide works by targeting the …

Goodyear Tire & Rubber (GT) sees 5.25% stake reported by Wellington

Wellington Management Group LLP and its affiliates have reported a beneficial ownership of 15,099,854 shares of The Goodyear Tire & Rubber Company common stock, which represents 5.25% of the class as of June 30, 2026. The filing indicates shared voting power over 12,474,869 shares …

BBVA Argentina announces Second Quarter 2026 Financial Results Schedule

BUENOS AIRES, Argentina, August 13, 2026--(BUSINESS WIRE)--Banco BBVA Argentina S.A. (NYSE; BYMA; MAE: BBAR; LATIBEX: XBBAR) today announced that it will report its Second Quarter 2026 financial results. Earnings Release Thursday, Aug 27, 2026 Time: After market close Conference Call Friday, Aug 28, 2026 …

Hubbell Inc. stock underperforms Thursday when compared to competitors

Hubbell Inc. (HUBB) shares fell 1.13% on Thursday, closing at $507.10, despite a generally positive trading day for the broader stock market. The S&P 500 Index rose 0.65% and the Dow Jones Industrial Average increased by 0.13%. This marks the second consecutive day of …

BBVA Argentina enters quiet period ahead of Aug. 27 results

BBVA Argentina (BBAR) has announced its Second Quarter 2026 financial results schedule, entering a quiet period from August 13 through August 27, 2026. The earnings release is set for after market close on Thursday, August 27, 2026, followed by a conference call on Friday, …

Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory

Bristol Myers Squibb has chosen Houston, Texas, as the location for its new state-of-the-art manufacturing facility. This 60,000-square-foot site represents a $2.3 billion investment and is projected to create 500 skilled jobs in Generation Park. Construction is set to begin next year, with the …

Chubb Limited Declares Quarterly Dividend, Payable on October 2, 2026

Chubb Limited's Board of Directors has declared a quarterly dividend of $1.02 per share. This dividend is payable on October 2, 2026, to shareholders who are on record as of the close of business on September 11, 2026.

Appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb over delayed drug approvals

A federal appeals court has reinstated a $6.7 billion lawsuit against Bristol Myers Squibb, brought by UMB Bank on behalf of former Celgene shareholders. The suit alleges Bristol Myers deliberately delayed FDA approvals for three drugs, including the cancer therapy Breyanzi, to avoid payouts …

TBBB Stock Jumps As BBB Foods Delivers Big Q2 Beat

TBBB Stock Jumps As BBB Foods Blows Past Q2 Revenue Targets

The Sharpest Exchanges From ABBV’s Earnings Call

Chubb Limited Board Declares Quarterly Dividend

ZURICH, Aug. 13, 2026 /PRNewswire/ -- The Board of Directors of Chubb Limited (NYSE: CB) today declared a quarterly dividend equal to $1.02 per share, payable on October 2, 2026 to shareholders of record at the close of business on September 11, 2026. The …

Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation

Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts. For Biogen, Wolfe raised its rating from Peer Perform and set a $300 price target, arguing that the …

Shareholders Will Receive Chubb's $1.02 Dividend on Oct. 2

Chubb Limited (NYSE: CB) has declared a quarterly dividend of $1.02 per share. This dividend is payable on October 2, 2026, to shareholders of record as of September 11, 2026. This represents the second installment of the dividend approved by shareholders on May 21, …

Abbott Laboratories (NYSE:ABT) Raised to Outperform at Wolfe Research

Wolfe Research upgraded Abbott Laboratories (NYSE:ABT) to "outperform" from "peer perform," setting a $130 price target, which suggests a 17.2% upside. This upgrade comes after Abbott's recent quarterly results surpassed expectations, with EPS of $1.31 and revenue of $12.59 billion, an increase of 13% …